Graduation Date

Fall 8-9-2017


One-year Embargo

Submission Type


Degree Name





School of Pharmacy

Committee Chair

Lauren A O'Donnell

Committee Member

Paula A. Witt-Enderby

Committee Member

Christopher Surratt

Committee Member

Wilson S. Meng

Committee Member

Kerry Empey


Interferon-gamma, neonatal, T cells, natural killer cells, microglia, Measles virus


Neonates are highly susceptible to infections in the central nervous system (CNS) and have a greater risk of viral infections and encephalopathies. Neurotropic viral infections can lead to blindness, hearing loss and neurological deficiencies such as cognitive impairment, epilepsy, and even death in the neonatal and pediatric populations. Viral infections also are hypothesized to indirectly contribute to neurodegenerative and neuropsychiatric diseases such as Schizophrenia and Parkinson’s disease later in life due to early neuronal damage or stress. Many diverse viruses are capable of invading the neonatal CNS including Borna Disease Virus, Coxsackievirus (CV), Herpes simplex viruses (HSV), and measles virus. Although, we understand that many viruses can cause CNS disease, the mechanisms of viral pathogenesis in the brain and the character of the neonatal anti-viral immune response are not well understood. However, it is hypothesized that neurological damage results from the combined effect of the virus and the immune response. Therefore, it is critical to develop immune-mediated strategies to promote viral clearance from the CNS while preventing neuronal damage or loss. This remains a challenge during neonatal CNS infections because of the uniquely immature nature of the neonatal immune system and the sensitivity of developing neurons to inflammation. In order to better understand how the neonatal immune response behaves in the brain, we use neurotropic measles virus (MV) as a model to understand the deficits in the neonatal immunity. Measles is a single-stranded, negative-sense RNA virus that is highly contagious in humans. Typical infection involves inhalation of infected respiratory droplets, infection of dendritic cells and macrophages in the respiratory tract resulting in transient immunosuppression, and a characteristic fever and rash. However, in some cases, MV also causes severe neurological diseases such as Post-infectious encephalomyelitis (PIE), Subacute sclerosing panencephalitis (SSPE), and Measles inclusion body encephalitis (MIBE). Currently, there is no cure for these MV-related neurological conditions, which occur overwhelmingly in newborns and children. Thus, the goal of this project is to define how neonatal immunity responds to MV infection in the unique microenvironment of the brain.

The role of interferon-gamma (IFNg), a key anti-viral cytokine in controlling adult CNS infections, was explored during a neuronally-restricted MV infection in the neonatal brain. We hypothesized that neonatal mice would be deficient in either IFNg production or in the infiltration of IFNg-producing immune cells in the brain. In order to address this question, we utilized the CD46+ mouse model, in which the human CD46+ receptor for MV is expressed only in mature neurons of the CNS. We explored the differences in the neonatal immune response, where the mice succumb to MV infection, and compared that to the CD46+ adults, which successfully control MV and survive. Our findings suggest that IFNg, which is critical for viral control and survival in adults, only delays mortality in CD46+ neonates. The neonatal brains also show the infiltration of natural killer cells, neutrophils, infiltrating monocytes and T cells in an IFNg-independent manner, all of which are capable of contributing to the IFNg pool. However, neonates and adults differentially express pathogen recognition receptors (e.g. Toll-like receptors) and Type I interferons during infection in the CNS, which suggests that the initial recognition of the virus by the immune system may differ in an age-dependent manner. Both neonates and adults expressed IFNg, CXCL10, IL-1, and IL-1RA, among other cytokines/chemokines. Regardless, CD46+ neonates succumb to infection despite mounting a Th1-like, but apparently defective, inflammatory response. We further explored whether there are age-dependent differences in IFNg signalling given that both ages of mice expressed this critical cytokine. Both neonatal and adult CD46+ mice express similar levels of IFNg but only adults show robust induction of the IFNg-responsive genes CIITA and CXCL9. This suggests that IFNg signaling may be defective in the induction of IFNg-responsive genes in neonates compared to adults.

To dissect the role of individual components of the immune system, we utilized CD46+ mice crossed to specific immune knockouts: CD46+/IFNg-KO mice, which lack IFNg, and CD46+/RAG2-KO mice, which lack mature B and T cells. We found that neonates lacking IFNg succumbed more rapidly than wildtype CD46+ mice, while neonates lacking mature B and T cells showed delayed morbidity and mortality. Neonates without IFNg show high infiltration of neutrophils and inflammatory monocytes but similar numbers of NK cell infiltration compared to CD46+ neonates. CD46+/IFNg-KO neonatal brains also show high infiltration of CD4 and CD8 T cells at the later stages of MV infection. Additionally, IFNα is significantly upregulated in the absence of IFNg in the brain post-MV infection. Thus, compensatory cytokines and high immune cell infiltration may contribute to uncontrolled inflammation and earlier death in CD46+/IFNg-KO neonates. CD46+ mice deficient in T-cells and B-cells (CD46+/RAG2-KO) show prolonged survival and mount a robust IFNβ response post-MV infection. This suggests that the adaptive immune response may be detrimental during the neonatal period, potentially leading to greater tissue damage. Additionally, CD46+/RAG2-KO neonates alone upregulate unique genes such as bone morphogenetic proteins (BMPs), which may mediate neuroprotection. Thus, these results suggest age-dependent expression of cytokine profiles in the brain and distinct dynamic interplays between lymphocyte populations and cytokines/chemokines in MV-infected neonates.



Available for download on Monday, December 10, 2018